PE20060853A1 - 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen - Google Patents

18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen

Info

Publication number
PE20060853A1
PE20060853A1 PE2006000006A PE2006000006A PE20060853A1 PE 20060853 A1 PE20060853 A1 PE 20060853A1 PE 2006000006 A PE2006000006 A PE 2006000006A PE 2006000006 A PE2006000006 A PE 2006000006A PE 20060853 A1 PE20060853 A1 PE 20060853A1
Authority
PE
Peru
Prior art keywords
methyl
pregn
carbolactones
well
pharmaceutical preparations
Prior art date
Application number
PE2006000006A
Other languages
English (en)
Inventor
Rolf Bohlmann
Dieter Bittler
Peter Esperling
Karl-Heinrich Fritzemeier
Katja Prelle
Steffen Borden
Ulrike Fuhrmann
Hans-Peter Muhn
Hermann Kunzer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36087369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20060853A1 publication Critical patent/PE20060853A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A COMPUESTOS 18-METIL-19-NOR-17-PREGN-4-EN-21,17-CARBOLACTONAS DE FORMULA (I), EN DONDE Z ES O, H, =NOR O =NNHSO2R, DONDE R ES H O ALQUILO; R4 ES H, HALOGENO, METILO O TRIFLUOROMETILO; R6 Y/O R7 PUEDEN ESTAR EN POSICION * O ß, Y SON INDEPENDIENTEMENTE, ALQUILO LINEAL O RAMIFICADO; O R6 ES H Y R7 ES ALQUILO; O JUNTOS FORMAN UN METILENO O UN ENLACE ADICIONAL. SON PREFERIDOS: 18-METIL-15ß,16ß-METILEN-3-OXO-19-NOR-17-PREGNA-4,6-DIEN-21,17-CARBOLACTONA, 18-METIL-6*,7*-15ß,16ß-DIMETILEN-3-OXO-19-NOR-17-PREGN-4-EN-21,17-CARBOLACTONA, ENTRE OTROS. TAMBIEN SE REFIEERE A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y QUE ADEMAS PUEDE CONTENER AL MENOS UN ESTROGENO TAL COMO ETINILESTRADIOL O UN ESTROGENO NATURAL TAL COMO VALERATO DE ESTRADIOL. ESTOS COMPUESTOS PESENTAN UNA ACCION GESTAGENICA Y ANTIMIERALOCORTICOIDE, POR LO QUE SON APROPIADOS PARA LA ANTICONCEPCION ORAL Y EN TRATAMIENTOS DE TRANSTORNOS PRE, PERI Y POSMENOPAUSICOS
PE2006000006A 2004-12-30 2006-01-03 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen PE20060853A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004063864A DE102004063864A1 (de) 2004-12-30 2004-12-30 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
PE20060853A1 true PE20060853A1 (es) 2006-09-15

Family

ID=36087369

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009001212A PE20100736A1 (es) 2004-12-30 2006-01-03 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
PE2006000006A PE20060853A1 (es) 2004-12-30 2006-01-03 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009001212A PE20100736A1 (es) 2004-12-30 2006-01-03 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen

Country Status (33)

Country Link
US (1) US20090029953A1 (es)
EP (1) EP1831240B8 (es)
JP (1) JP5043681B2 (es)
KR (1) KR20070093443A (es)
CN (1) CN101128476B (es)
AR (1) AR052657A1 (es)
AU (1) AU2005324055A1 (es)
BR (1) BRPI0518533A2 (es)
CA (1) CA2594171C (es)
CR (1) CR9223A (es)
CY (1) CY1109498T1 (es)
DE (2) DE102004063864A1 (es)
DK (1) DK1831240T3 (es)
EA (1) EA014325B1 (es)
ES (1) ES2331322T3 (es)
GT (1) GT200500394A (es)
HK (1) HK1112627A1 (es)
IL (1) IL184288A (es)
MX (1) MX2007008074A (es)
MY (1) MY145904A (es)
NO (1) NO20073257L (es)
NZ (1) NZ556150A (es)
PA (1) PA8658401A1 (es)
PE (2) PE20100736A1 (es)
PL (1) PL1831240T3 (es)
PT (1) PT1831240E (es)
RS (1) RS51128B (es)
SI (1) SI1831240T1 (es)
TW (1) TW200635942A (es)
UA (1) UA90496C2 (es)
UY (1) UY29320A1 (es)
WO (1) WO2006072467A1 (es)
ZA (1) ZA200706254B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063501A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063500A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063495A1 (de) 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063499A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063503A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2265629B1 (en) * 2008-03-05 2015-06-24 Evestra, Inc. Bismethylene-17 carbolactones and related uses
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
EP2367808A4 (en) * 2008-11-25 2012-05-09 Evestra Inc g-LACTONES OF 3- (6,6-ETHYLENE-17β-HYDROXY-3-OXO-17α-PREGEN-4-EENE-17α-YL) PROGESTATIVE PROPIONIC ACID
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone

Also Published As

Publication number Publication date
KR20070093443A (ko) 2007-09-18
UA90496C2 (ru) 2010-05-11
EA014325B1 (ru) 2010-10-29
JP2008526709A (ja) 2008-07-24
NZ556150A (en) 2011-02-25
CY1109498T1 (el) 2014-08-13
CR9223A (es) 2007-11-23
MY145904A (en) 2012-05-15
IL184288A0 (en) 2007-10-31
TW200635942A (en) 2006-10-16
PA8658401A1 (es) 2006-08-03
HK1112627A1 (es) 2008-09-12
EA200701239A1 (ru) 2007-12-28
PE20100736A1 (es) 2010-12-03
RS51128B (sr) 2010-10-31
DK1831240T3 (da) 2009-11-23
SI1831240T1 (sl) 2009-12-31
BRPI0518533A2 (pt) 2008-11-25
ZA200706254B (en) 2008-12-31
JP5043681B2 (ja) 2012-10-10
DE502005007723D1 (de) 2009-08-27
IL184288A (en) 2011-06-30
UY29320A1 (es) 2006-07-31
ES2331322T3 (es) 2009-12-29
NO20073257L (no) 2007-08-29
GT200500394A (es) 2006-08-01
AR052657A1 (es) 2007-03-28
EP1831240A1 (de) 2007-09-12
CN101128476B (zh) 2011-02-09
US20090029953A1 (en) 2009-01-29
MX2007008074A (es) 2008-03-10
AU2005324055A1 (en) 2006-07-13
CN101128476A (zh) 2008-02-20
EP1831240B8 (de) 2010-02-17
CA2594171A1 (en) 2006-07-13
PT1831240E (pt) 2009-10-22
EP1831240B1 (de) 2009-07-15
WO2006072467A1 (de) 2006-07-13
CA2594171C (en) 2012-10-16
DE102004063864A1 (de) 2006-07-13
PL1831240T3 (pl) 2010-01-29

Similar Documents

Publication Publication Date Title
PE20060853A1 (es) 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
PE20080995A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
DK1089722T3 (da) Transdermalt plaster af matrixtypen til steroidhormoner
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
DK1157037T3 (da) GCSF-konjugater
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
IL151371A (en) Modified porcine factor viii and pharmaceutical compositions containing the same
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
AR023497A1 (es) Ent-esteroides en calidad de estrogenos con efecto selectivo, su empleo para el tratamiento de las enfermedades y los estados motivados por una deficienciade estrogenos en la mujer y en el hombre, y las composiciones farmaceuticas que contienen estos ent-esteroides
PE20070327A1 (es) Composicion que comprende una progestina y un estrogeno
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
BR0203902A (pt) Composições de compostos bioquìmicos envolvidos no metabolismo bioenergético das células e método de uso da mesma
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
NI200700331A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AR015222A1 (es) Benzotiadiazoles, proceso para su preparacion, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
DE602004005564D1 (de) Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물

Legal Events

Date Code Title Description
FC Refusal